VIENCE
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
VIENCE - overview
Established
2022
Location
Seoul, -, South Korea
Primary Industry
Biotechnology
About
Based in Seoul, South Korea, and founded in 2022, VIENCE operates as a bioinformatics company that provides cloud-based scientific analysis and medical diagnosis using artificial intelligence technology. In December 2023, VIENCE raised KRW 200 million in seed funding from CNTTech and DB Capital. As of January 2024, the company is led by its CEO Jeong Won-gi. VIENCE products offering includes VIENCE CANVAS, VIENCE PATHOVIEW, and VIENCE NEUROVIEW.
These products are designed to streamline data analysis processes across various domains. VIENCE CANVAS stands as a visual programming platform that allows users to leverage technology through simple interactions, enabling the construction of robust data analysis workflows. Meanwhile, VIENCE PATHOVIEW and VIENCE NEUROVIEW cater to specific domains, ensuring tailored and optimized solutions for pathology and neurology research.
Current Investors
CNTTech, DB Capital
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Analytics & Performance Software
Website
www.vience.io
Verticals
Artificial Intelligence, Big Data
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.